Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for carotid intima-media thickness in adults with type 2 diabetes and prior transient ischemic attack
IRCT20221101056357N4Phase 3Recruiting
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, single-blind trial of tirzepatide in transient ischaemic attack (TIA), type 2 diabetes mellitus (T2DM) and carotid atheroma (CAS) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoint: Change in mean carotid intima-media thickness. Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
transient ischaemic attack (TIA)type 2 diabetes mellitus (T2DM)carotid atheroma (CAS)
Beyond the preview
Go deeper on IRCT20221101056357N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221101056357N4.